Get the Stockscreener App
27.90
8.73%
2.24
Quidelortho Corporation stock is traded at $27.90, with a volume of 1.75M.
It is up +8.73% in the last 24 hours and up +9.24% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
See More
Previous Close:
$25.66
Open:
$26.47
24h Volume:
1.75M
Relative Volume:
1.25
Market Cap:
$1.89B
Revenue:
$2.74B
Net Income/Loss:
$-441.40M
P/E Ratio:
-4.2661
EPS:
-6.54
Net Cash Flow:
$13.00M
1W Performance:
+7.60%
1M Performance:
+9.24%
6M Performance:
-31.04%
1Y Performance:
-35.65%
1-Day Range:
$25.92
$28.22
1-Week Range:
$25.43
$28.22
52-Week Range:
$22.05
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
27.90 | 1.75B | 2.74B | -441.40M | 13.00M | -6.54 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
QuidelOrtho's Strategic Leadership Reinforcement and Growth Potential: A Catalyst for Diagnostics Sector Transformation - AInvest
QuidelOrtho's Strategic Leadership Addition and Growth Potential: Leveraging Erich Wolff's Expertise for Inorganic Growth - AInvest
QuidelOrtho names Erich Wolff as EVP of strategy & corporate development - Investing.com
QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development | QDEL Stock News - GuruFocus
Quidelortho welcomes Erich Wolff as EVP, strategy & corporate development - MarketScreener
QuidelOrtho Appoints Erich Wolff as Executive Vice President, Strategy & Corporate Development. - AInvest
QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development - Barchart.com
QuidelOrtho Corporation Recovers — But Is It Sustainable2025 Top Gainers & AI Enhanced Trade Execution Alerts - newsyoung.net
Multi Factor Analysis Ranks QuidelOrtho Corporation as Strong Buy2025 Top Decliners & Technical Buy Zone Confirmation - newsyoung.net
When is the best time to buy QuidelOrtho Corporation stockChart Signals & Consistent Profit Trading Strategies - beatles.ru
QuidelOrtho (QDEL): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Fibonacci Retracement Aligns with Support in QuidelOrtho CorporationQuarterly Trade Report & Weekly Watchlist for Consistent Profits - sundaytimes.kr
QuidelOrtho launches certified analyser programme for rural health facilities - Yahoo Finance
QuidelOrtho Launches Certified Analyzer Program to Enhance Diagnostic Access in Rural Areas - AInvest
Is QuidelOrtho's (QDEL) Steadfast Revenue Outlook a Sign of Management Conviction or Overconfidence? - simplywall.st
Visual trend scoring systems applied to QuidelOrtho Corporation2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - Newser
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know - MSN
QuidelOrtho launches certified analyzer program for rural healthcare - Investing.com
QuidelOrtho launches certified analyzer program for rural healthcare By Investing.com - Investing.com Nigeria
QuidelOrtho's Strategic Expansion in Point-of-Care Diagnostics: A Pathway to Long-Term Value Creation - AInvest
QuidelOrtho Launches Certified Analyzer Program | QDEL Stock News - GuruFocus
QuidelOrtho Launches Certified Analyzer Program to Expand Diagnostic Testing in Underserved Communities - AInvest
QuidelOrtho launches certified analyzer program for underserved areas - StreetInsider
QuidelOrtho Launches Certified Analyzer Program - WV News
The Top 5 Analyst Questions From QuidelOrtho’s Q2 Earnings Call - Yahoo Finance
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - Yahoo Finance
AI Tools Suggest QuidelOrtho Corporation May Outperform This WeekRisk Managed Intraday Trade Alerts Increase in Volume - 선데이타임즈
Earnings Release: Here's Why Analysts Cut Their QuidelOrtho Corporation (NASDAQ:QDEL) Price Target To US$43.14 - 富途牛牛
Published on: 2025-08-09 08:22:34 - beatles.ru
There's No Escaping QuidelOrtho Corporation's (NASDAQ:QDEL) Muted Revenues Despite A 29% Share Price Rise - 富途牛牛
Will QuidelOrtho's (QDEL) Renewed Cost Discipline Strengthen Its Long-Term Growth Story? - simplywall.st
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
QuidelOrtho narrows China outlook to mid-single-digit growth as cost actions drive margin gains - MSN
QuidelOrtho’s Earnings Call: Mixed Sentiment with Global Growth - The Globe and Mail
QuidelOrtho Topped Estimates But Still Posted A Net Loss - Finimize
QuidelOrtho (QDEL) Analyst Rating Update: UBS Lowers Price Target | QDEL Stock News - GuruFocus
QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand - MSN
UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating - MarketScreener
Should Value Investors Buy QuidelOrtho (QDEL) Stock? - Yahoo Finance
QuidelOrtho 2025 Q2 Earnings Widens Losses Amid Revenue Decline - AInvest
QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2025 Earnings Call Transcript - Insider Monkey
QuidelOrtho Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
QuidelOrtho Q2 Revenue Beats Estimate, EPS Turns Positive Amid Restructuring Costs. - AInvest
QuidelOrtho Q2 2025 Earnings: Adjusted EPS Beats Estimates, Revenue Hits $614 Million - AInvest
Citigroup Reiterates Buy on QuidelOrtho, PT Lowered to $40 - AInvest
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats - AOL.com
QuidelOrtho shares rise 14.02% premarket after reporting Q2 earnings with improved EBITDA margin and cost savings. - AInvest
QuidelOrtho Stock Soars 10.85% on Q2 Earnings Beat - AInvest
Citi Adjusts QuidelOrtho (QDEL) Price Target, Maintains Buy Rati - GuruFocus
QuidelOrtho 2025 Q2 Earnings Deeper Losses Amid Revenue Decline - AInvest
QuidelOrtho revenue decreases to USD 614M in Q2 2025 - Medical Buyer
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):